WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 555674
CAS#: 790186-68-4
Description: GW284543, also known as UNC10225170;, is a potent and selective MEK5 inhibitor with the potential for cancer treatment.
MedKoo Cat#: 555674
Name: GW284543
CAS#: 790186-68-4
Chemical Formula: C23H20N2O3
Exact Mass: 372.1474
Molecular Weight: 372.424
Elemental Analysis: C, 74.18; H, 5.41; N, 7.52; O, 12.89
Synonym: GW284543; GW-284543; GW 284543; UNC10225170; UNC-10225170; UNC 10225170;
IUPAC/Chemical Name: 6,7-dimethoxy-N-(3-phenoxyphenyl)quinolin-4-amine
InChi Key: LEEMRFWMAIVHQY-UHFFFAOYSA-N
InChi Code: InChI=1S/C23H20N2O3/c1-26-22-14-19-20(11-12-24-21(19)15-23(22)27-2)25-16-7-6-10-18(13-16)28-17-8-4-3-5-9-17/h3-15H,1-2H3,(H,24,25)
SMILES Code: COC1=CC2=C(NC3=CC(OC4=CC=CC=C4)=CC=C3)C=CN=C2C=C1OC
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
| Biological target: | GW284543 (UNC10225170) is a selective MEK5 inhibitor. |
| In vitro activity: | UNC10225170 treatment dose-dependently inhibited MEK5, as determined by reductions in pERK5, and decreased endogenous MYC protein (Figure 6C). Reference: Cancer Cell. 2018 Nov 12;34(5):807-822.e7. doi https://pubmed.ncbi.nlm.nih.gov/30423298/ |
| In vivo activity: | TBD |
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 67.0 | 179.9 |
The following data is based on the product molecular weight 372.424 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | 1. Vaseva AV, Blake DR, Gilbert TSK, Ng S, Hostetter G, Azam SH, Ozkan-Dagliyan I, Gautam P, Bryant KL, Pearce KH, Herring LE, Han H, Graves LM, Witkiewicz AK, Knudsen ES, Pecot CV, Rashid N, Houghton PJ, Wennerberg K, Cox AD, Der CJ. KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism. Cancer Cell. 2018 Nov 12;34(5):807-822.e7. doi: 10.1016/j.ccell.2018.10.001. PMID: 30423298; PMCID: PMC6321749. |
| In vitro protocol: | 1. Vaseva AV, Blake DR, Gilbert TSK, Ng S, Hostetter G, Azam SH, Ozkan-Dagliyan I, Gautam P, Bryant KL, Pearce KH, Herring LE, Han H, Graves LM, Witkiewicz AK, Knudsen ES, Pecot CV, Rashid N, Houghton PJ, Wennerberg K, Cox AD, Der CJ. KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism. Cancer Cell. 2018 Nov 12;34(5):807-822.e7. doi: 10.1016/j.ccell.2018.10.001. PMID: 30423298; PMCID: PMC6321749. |
| In vivo protocol: | TBD |
